Abstract:Background: Metabolic dysfunction and neuroinflammation are increasingly implicated in Parkinson's disease (PD). The pentose phosphate pathway (PPP, a metabolic pathway parallel to glycolysis) converts glucose-6-phosphate into pentoses and generates ribose-5-phosphate and NADPH thereby governing anabolic biosynthesis and redox homeostasis. Brains and immune cells display high activity of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP. A postmortem study reveals dysregulation of G6PD enzyme in brains of PD patients. However, spatial and temporal changes in activity/expression of G6PD in PD remain undetermined. More importantly, it is unclear how dysfunction of G6PD and the PPP affects neuroinflammation and neurodegeneration in PD. Methods: We examined expression/activity of G6PD and its association with microglial activation and dopaminergic neurodegeneration in multiple chronic PD models generated by an intranigral/intraperitoneal injection of LPS, daily subcutaneous injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 6 days, or transgenic expression of A53T α-synuclein. Primary microglia were transfected with G6PD siRNAs and treated with lipopolysaccharide (LPS) to examine effects of G6PD knockdown on microglial activation and death of co-cultured neurons. LPS alone or with G6PD inhibitor(s) was administrated to mouse substantia nigra or midbrain neuron-glia cultures. While histological and biochemical analyses were conducted to examine microglial activation and dopaminergic neurodegeneration in vitro and in vivo, rotarod behavior test was performed to evaluate locomotor impairment in mice. Results: Expression and activity of G6PD were elevated in LPS-treated midbrain neuron-glia cultures (an in vitro PD model) and the substantia nigra of four in vivo PD models. Such elevation was positively associated with microglial activation and dopaminergic neurodegeneration. Furthermore, inhibition of G6PD by 6-aminonicotinamide and dehydroepiandrosterone and knockdown of microglial G6PD attenuated LPS-elicited chronic dopaminergic neurodegeneration. Mechanistically, microglia with elevated G6PD activity/expression produced excessive NADPH and provided abundant substrate to over-activated NADPH oxidase (NOX2) leading to production of excessive reactive oxygen species (ROS). Knockdown and inhibition of G6PD ameliorated LPS-triggered production of ROS and activation of NF-кB thereby dampening microglial activation. Conclusions: Our findings indicated that G6PD-mediated PPP dysfunction and neuroinflammation exacerbated each other mediating chronic dopaminergic neurodegeneration and locomotor impairment. Insight into metabolic-inflammatory interface suggests that G6PD and NOX2 are potential therapeutic targets for PD.

Microglia P2Y6 receptor is related to Parkinson’s disease through neuroinflammatory process

Prostaglandin E 2 Receptor Subtype 2 (EP2) Regulates Microglial Activation and Associated Neurotoxicity Induced by Aggregated Α-Synuclein

Brain microglia activation and peripheral adaptive immunity in Parkinson's disease: a multimodal PET study

Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson's Disease

Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson’s Disease

Inflammatory neuronal loss in the substantia nigra induced by systemic lipopolysaccharide is prevented by knockout of the P2Y6 receptor in mice

Single-cell RNA sequencing reveals peripheral immunological features in Parkinson's Disease

GSDMD in Peripheral Myeloid Cells Regulates Microglial Immune Training and Neuroinflammation in Parkinson's Disease

Microglial SIX2 suppresses lipopolysaccharide (LPS)-induced neuroinflammation by up-regulating FXYD2 expression

GSDMD in peripheral myeloid cells regulates microglial immune training and neuroinflammation in Parkinson’s disease

Microglial MT1 activation inhibits LPS‐induced neuroinflammation via regulation of metabolic reprogramming

Regulation of miR-590-5p on Neurological Inflammation and Oxidative Stress and Its Biomarker Role in Parkinson's Disease

LncRNA DLX6-AS1 promotes microglial inflammatory response in Parkinson's disease by regulating the miR-223–3p/NRP1 axis

The microglial P2Y6 receptor as a therapeutic target for neurodegenerative diseases

The pentose phosphate pathway regulates chronic neuroinflammation and dopaminergic neurodegeneration

LncRNA DLX6-AS1 promotes microglial inflammatory response in Parkinson?s disease by regulating the miR-223-3p/NRP1 axis

Inhibiting Purinergic P2x7 Receptors with the Antagonist Brilliant Blue G is Neuroprotective in an Intranigral Lipopolysaccharide Animal Model of Parkinson'S Disease

Modification of Neural Circuit Functions by Microglial P2Y6 Receptors in Health and Neurodegeneration

CysLT 2 Receptor Mediates Lipopolysaccharide-Induced Microglial Inflammation and Consequent Neurotoxicity in Vitro

Regulation of Mir-590-5p on Neurological Inflammation and Oxidative Stress and Its Biomarker Role in Parkinson’s Disease

P2Y6 receptor and immunoinflammation